Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chemotherapy

Irinotecan or etoposide as front-line therapy for SCLC?

Nature Reviews Clinical Oncology volume 6, pages 562–563 (2009)Cite this article

The results of a large, randomized, North American trial (SWOG S0124) that compared etoposide and cisplatin with irinotecan and cisplatin for patients with extensive small-cell lung cancer have failed to confirm the benefit observed with irinotecan that was demonstrated in an earlier Japan Clinical Oncology Group study (JCOG 9511).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Noda, K. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346, 85–91 (2002).

    Article  CAS  Google Scholar 

  2. Hanna, N. et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24, 2038–2043 (2006).

    Article  CAS  Google Scholar 

  3. Lara, P. N., Jr et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 27, 2530–2535 (2009).

    Article  CAS  Google Scholar 

  4. Hermes, A. et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J. Clin. Oncol. 26, 4261–4267 (2008).

    Article  CAS  Google Scholar 

  5. Schmittel, A. H. Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial [abstract]. ASCO Meeting Abstracts 27, 8029 (2009).

    Google Scholar 

  6. Palomaki, G. E., Bradley, L. A., Douglas, M. P., Kolor, K. & Dotson, W. D. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet. Med. 11, 21–34 (2009).

    Article  CAS  Google Scholar 

  7. Gandara, D. R. et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27, 3540–3546 (2009).

    Article  CAS  Google Scholar 

  8. Glisson, B. S. Recurrent small cell lung cancer: update. Semin. Oncol. 30, 72–78 (2003).

    Article  Google Scholar 

  9. Inoue, A. et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J. Clin. Oncol. 26, 5401–5406 (2008).

    Article  CAS  Google Scholar 

  10. Eckardt, J. R. et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J. Clin. Oncol. 25, 2086–2092 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Faye M. Johnson & Bonnie S. Glisson

Authors
  1. Faye M. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bonnie S. Glisson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bonnie S. Glisson.

Ethics declarations

Competing interests

B. S. Glisson declares the receipt of grant/research support from Pfizer Inc. F. M. Johnson declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnson, F., Glisson, B. Irinotecan or etoposide as front-line therapy for SCLC?. Nat Rev Clin Oncol 6, 562–563 (2009). https://doi.org/10.1038/nrclinonc.2009.141

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.141

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing